文献速递眼底病与葡萄膜炎

抗VEGF药物摩尔剂量与早期视网膜脉络膜血流变化的关系

Association of Molar Dose and Early Retinochoroidal Blood Flow Changes After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

该回顾性系列纳入61眼新生血管性年龄相关性黄斑变性(nAMD),比较四种抗VEGF药物注射后30分钟视盘血管和脉络膜血流的百分比变化。阿柏西普8 mg组视盘血管血流平均下降11.2%(P=0.001),脉络膜血流下降13.7%(P<0.001);脉络膜血流下降与摩尔剂量呈显著负相关(Spearman ρ=-0.395,P=0.002),且阿柏西普8 mg的脉络膜血流下降大于阿柏西普2 mg(P=0.019)。

要点

  • 阿柏西普8 mg注射后30分钟视盘血管血流下降11.2%,脉络膜血流下降13.7%。
  • 脉络膜血流下降与抗VEGF药物摩尔剂量呈负相关(ρ=-0.395,P=0.002)。
  • 阿柏西普8 mg的脉络膜血流下降显著大于阿柏西普2 mg(P=0.019)。

核心结论

  • 阿柏西普8 mg注射后30分钟产生显著眼血流下降,脉络膜血流下降与摩尔剂量负相关,提示浓度依赖性血流动力学效应。

研究设计与样本

  • 回顾性系列研究,纳入61眼nAMD,其中15眼接受布罗鲁珠单抗、15眼法瑞西单抗、15眼阿柏西普2 mg、16眼阿柏西普8 mg。
  • 采用激光散斑血流图定量注射前和注射后30分钟视盘血管平均模糊率(ONH MBR-vessel)和脉络膜平均模糊率(CHOR MBR)。

主要发现

  • 阿柏西普8 mg组ONH MBR-vessel平均百分比变化为-11.2%±11.2%(P=0.001),CHOR MBR为-13.7%±7.5%(P<0.001)。
  • 阿柏西普8 mg与其他药物在ONH MBR-vessel百分比变化上无显著差异。
  • 阿柏西普8 mg的CHOR MBR下降显著大于阿柏西普2 mg(P=0.019)。
  • 摩尔剂量与ONH MBR-vessel百分比变化无显著相关性,与CHOR MBR百分比变化呈显著负相关(Spearman ρ=-0.395,P=0.002)。

临床怎么用

  • 对于nAMD患者,选择阿柏西普8 mg时需关注注射后早期脉络膜血流下降,尤其在高摩尔剂量下可能更明显。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to evaluate short-term intraocular blood flow changes post-intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection in patients with neovascular age-related macular degeneration (nAMD), compare reductions across 4 agents (brolucizumab, faricimab, aflibercept 2 mg, and aflibercept 8 mg), and examine correlations between each agent's molar dose and the magnitude of 30-minute blood flow change. METHODS: This retrospective series included 61 eyes with nAMD (15 treated with brolucizumab, 15 with faricimab, 15 with aflibercept 2 mg, and 16 with aflibercept 8 mg). Laser speckle flowgraphy quantified mean blur rate (MBR) at the optic nerve head vessels (ONH MBR-vessel) and choroid (CHOR MBR) before and 30 minutes post-injection. Percent changes (%ONH MBR-vessel, %CHOR MBR) were compared among groups, and correlations with molar dose were assessed. RESULTS: In the aflibercept 8 mg group, the mean percent changes were -11.2% ± 11.2% for ONH MBR-vessel (P = 0.001) and -13.7% ± 7.5% for CHOR MBR (P < 0.001). Pairwise comparisons showed no significant differences in %ONH MBR-vessel between aflibercept 8 mg and other agents. The reduction in %CHOR MBR was significantly greater with aflibercept 8 mg than with aflibercept 2 mg (P = 0.019). Molar dose was not significantly correlated with %ONH MBR-vessel, whereas %CHOR MBR showed a significant negative association with molar dose (Spearman ρ = -0.395, P = 0.002). CONCLUSIONS: Aflibercept 8 mg produced a significant 30-minute reduction in ocular blood flow. Choroidal flow reduction was greater than with aflibercept 2 mg and negatively correlated with molar dose, suggesting a concentration-dependent hemodynamic effect.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Kato N, Haruta M, Arai R, et al. Association of Molar Dose and Early Retinochoroidal Blood Flow Changes After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy. Invest Ophthalmol Vis Sci. 2025. PMID: 41533930. doi:10.1167/iovs.66.15.56

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。